Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement

Clinical and Experimental Rheumatology

Volumn 26, Issue 3 SUPPL. 49, 2008, Pages

  Roccatello, Dario ^a,b   Baldovino, Simone ^a,b   Alpa, Mirella ^a   Rossi, Daniela ^a   Napoli, Franca ^a   Naretto, Carla ^a   Cavallo, Roberto ^a   Giachino, Osvaldo ^a  

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Churg Strauss syndrome; Microscopic polyangiitis; Paucimmune necrotizing glomerulonephritis; Rituximab; Vasculitis; Wegener's granulomatosis

Indexed keywords

ANTIHISTAMINIC AGENT; C REACTIVE PROTEIN; CD20 ANTIBODY; CREATININE; CYCLOPHOSPHAMIDE; DEFLAZACORT; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PARACETAMOL; PREDNISONE; RITUXIMAB;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BRADYCARDIA; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ELECTRODIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; KIDNEY INJURY; LOW DRUG DOSE; MALE; MICROSCOPIC POLYANGIITIS; PANCYTOPENIA; PRIORITY JOURNAL; PROTEINURIA; WEAKNESS; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; CHURG-STRAUSS SYNDROME; COHORT STUDIES; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 52049126665     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
2. FALK RJ, GLASSOCK RJ: Glomerular, Vascular, and Tubulointerstitial Diseases. Neph-SAP 2006; 5: 339-404.
3. WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.
4. DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52: 2461-9.
5. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
6. ROCCATELLO D, BALDOVINO S, ROSSI D et al.: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004, 19: 3054-61.
7. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotising vasculitis. QJM 1994; 87: 671-8.
8. EXLEY AR, BACON PA, LUQMANI RA et al.: Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371-80.
9. KEOGH KA, WYLAM ME, STONE JH, SPECKS U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Rheum 2005; 52: 262-8.
10. KEOGH KA, YTTERBERG SR, FERVENZA FC, CARLSON KA, SCHROEDER DR, SPECKS U: Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-7.
11. ERIKSSON P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257: 540-8.
12. GOTTENBERG JE, GULLEVIN L, LAMBOTTE O et al.: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-20.
13. OMDAL R, WILDHAGEN K, HANSEN T, GUNNARSSON R, KRISTOFFERSEN G: Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response. Scand J Rheumatol 2005; 34: 229-232.
14. ARIES PM, HELLMICH B, VOSWINKEL J et al.: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-8.
15. BRIHAYE B, AOUBA A, PAGNOUX C, COHEN P, LACASSIN F, GUILLEVIN L: Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: A study on 8 patients. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S23-27.
16. FLOSSMANN O, JONES RB, JAYNE DRW, LUQMANI RA: Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis. Ann Rheum Dis 2006; 65: 841-4.
17. EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
18. ARIES PM, LAMPRECHT P, GROSS WL: Rituximab in refractory Wegener's granulomatosis: Favourable or not? Am J Respir Crit Care Med 2006; 173: 815-6.
19. POPA ER, STEGEMAN CA, BOS NA, KALLENBERG CG. TERVAERT JW: Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103 (Pt 1): 885-94.
20. KRUMBHOLZ M, SPECKS U, WICK M, KALLED SL, JENNE D, MEINL E: BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005; 25: 298-302.
21. MITCHISON NA: T-cell-B-cell cooperation. Nat Rev Immunol 2004, 4: 308-12.